Skip to content

Citius Oncology, Inc. CTOR Purchase Obligation

Purchase Obligation at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$1.7M
Gross profit$1.3M
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-75.9%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted.

The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s purchase obligation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s purchase obligation?
Citius Oncology, Inc. (CTOR) reported purchase obligation of $16.2M in Q3 2025.
What does purchase obligation mean?
This represents legally binding commitments to purchase goods or services from third parties in future periods. It provides insight into the company's future cash outflow requirements and operational dependencies. Monitoring these obligations is essential for assessing the company's liquidity position and its ability to meet contractual commitments.